A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas

被引：8

作者：

Mato, Anthony R. ^{[1
,2
]}

Schuster, Stephen J. ^{[3
]}

Foss, Francine M. ^{[4
]}

Isufi, Iris ^{[4
]}

Ding, Wei ^{[5
]}

Brander, Danielle M. ^{[6
]}

Sitlinger, Andrea ^{[7
]}

Tun, Han W. ^{[8
]}

Moustafa, Muhamad Alhaj ^{[9
]}

Kennard, Kaitlin ^{[3
]}

King, Cara M. ^{[3
]}

Koehler, Amber ^{[5
]}

Aitken, Casey ^{[5
]}

He, Wei ^{[10
]}

Kearney, Albert ^{[10
]}

Gui, Min ^{[10
]}

Anderson, Barry Douglas ^{[11
]}

Rosenthal, Allison C. ^{[12
]}

Roeker, Lindsey E. ^{[13
]}

Huntington, Scott F. ^{[14
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Hematol Malignancies Div, CLL Program, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[3] Univ Penn, Abramson Canc Ctr, Lymphoma Program, Philadelphia, PA 19104 USA

[4] Yale Univ, Sch Med, Hematol, New Haven, CT USA

[5] Mayo Clin, Rochester, MN USA

[6] Duke Univ, Med Ctr, Durham, NC USA

[7] Duke Univ, Med Ctr, Hematol Malignancies & Cellular Therapy, Durham, NC USA

[8] Mayo Clin, Div Hematol & Med Oncol, Jacksonville, FL 32224 USA

[9] Mayo Clin, Div Hematol & Med Oncol, Jacksonville, FL 32224 USA

[10] Zhejiang DTRM Biopharma LLC, Plymouth, Peoples R China

[11] Theradex Inc, Princeton, NJ USA

[12] Mayo Clin, Div Hematol & Oncol, Phoenix, AZ USA

[13] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[14] Yale Canc Ctr, New Haven, CT USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-126192

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

810

引用

页数：5

共 5 条

[1] A phase Ia/Ib study of a novel BTK inhibitor, DTRMWXHS-12 (DTRM 12), and combination products, with everolimus and pomalidomide, in pts with CLL or other B-cell lymphomas.
Gill, Jennifer
He, Wei
Schuster, Stephen J.
Brander, Danielle M.
Chatburn, Elizabeth
Kennard, Kaitlin
Anderson, Barry Douglas
Nasta, Sunita
Landsburg, Daniel Jeffrey
Porter, David L.
Napier, Ellen
Latorre, Tanya
Svoboda, Jakub
Addis, Victoria
Mato, Anthony R.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[2] Simultaneous Global Phase I Studies of a Differentiated BTK Inhibitor, Dtrmwxhs-12, in Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphomas
Song, Yuqin
Schuster, Stephen J.
He, Wei
Zhu, Jun
Deng, Lijuan
Sun, Yingli
Ding, Ning
Wang, Xiaogan
Gill, Jennifer
Chatburn, Elizabeth T.
Kennard, Kaitlin
Anderson, Barry Douglas
Nasta, Sunita Dwivedy
Landsburg, Daniel J.
Porter, David L.
Napier, Ellen
Hughes, Mitchell E.
Latorre, Tanya
Walsh, Kristy
Dorsey, Colleen
Svoboda, Jakub
Addis, Victoria
Mato, Anthony R.
BLOOD, 2017, 130
[3] DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study
Huntington, Scott F.
Schuster, Stephen J.
Ding, Wei
Koehler, Amber B.
Brander, Danielle M.
Rosenthal, Allison C.
Leis, Jose F.
Tun, Han W.
Moustafa, Muhamad Alhaj
Iqbal, Madiha
He, Wei
Kearney, Albert S.
McKinlay, Timothy P.
Gui, Min
Mato, Anthony R.
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (05) : 739 - 749
[4] A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM)
Yap, Timothy A.
Winter, Jane N.
Leonard, John P.
Ribrag, Vincent
Constantinidou, Anastasia
Giulino-Roth, Lisa
Michot, Jean-Marie
Khan, Tariq A.
Horner, Thierry
Carver, Jennifer
Dumetrescu, Teodora Pene
He, Zangdong
McCabe, Michael T.
Creasy, Caretha L.
Dhar, Arindam
Carpenter, Christopher
Johnson, Peter M.
BLOOD, 2016, 128 (22)
[5] A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkin's lymphomas (NHL), multiple myeloma (MM) and solid tumor.
Yap, Timothy Anthony
Johnson, Peter W. M.
Winter, Jane
Leonard, John
Giulino-Roth, Lisa
Horner, Thierry
Radswillas, Kristen
Carver, Jennifer
Dhar, Arindam
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 →